Key Highlights
• 43% First-Cycle Complete Remission Rate: The Annamycin plus HiDAC combination achieved 43% and 36% first-cycle complete remission rates versus 12% in the HiDAC monotherapy control arm.
• Composite CR Rates Reach 57%: Composite complete remission rates of up to 57% represent a clinically meaningful improvement over the control arm.
• Strong Validation for Ongoing Enrollment: The data supports continued enrollment and final dose optimization in the ongoing MIRACLE trial.
Moleculin Biotech (NASDAQ: MBRX) released encouraging interim results from its Phase 2/3 MIRACLE trial evaluating the combination of Annamycin and High-Dose Cytarabine (HiDAC) in patients with relapsed or refractory acute myeloid leukemia, demonstrating superior efficacy over HiDAC monotherapy across all primary efficacy measures.
The data revealed first-cycle complete remission rates of 43% and 36% across different dose cohorts of the Annamycin plus HiDAC combination, compared to just 12% in the HiDAC monotherapy control arm, representing a three to four-fold improvement in the proportion of patients achieving the most clinically meaningful early response.
Composite complete remission rates, which capture patients achieving complete remission with or without full count recovery, reached as high as 57% in the combination arm, providing additional evidence of the treatment's clinical activity in a patient population that historically faces extremely poor outcomes with standard salvage chemotherapy.
Relapsed and refractory acute myeloid leukemia represents one of the most difficult-to-treat cancer subsets in all of oncology. Most patients who relapse after initial induction chemotherapy or who fail to respond to frontline treatment have very limited options, with response rates to standard salvage regimens typically in the range of 10% to 30%, making the MIRACLE trial's combination arm results clinically noteworthy.
The interim data provides strong validation for continued enrollment in the ongoing trial and will inform the final dose optimization strategy for Annamycin within the combination regimen. Moleculin Biotech (NASDAQ: MBRX) will need to complete enrollment and generate final data to support a potential regulatory submission, though the interim results represent a meaningfully positive signal for the program's development trajectory.
()
FAQs
Q: What is relapsed or refractory acute myeloid leukemia and why is it so difficult to treat?
A: Relapsed AML refers to cancer that returns after initially responding to treatment, while refractory AML refers to disease that fails to respond to initial therapy. Both represent highly aggressive disease states where standard chemotherapy produces low response rates, typically 10-30%, and long-term survival remains poor, representing a significant unmet medical need.
Q: What is Annamycin and how does it differ from standard AML treatments?
A: Annamycin is a reformulated anthracycline compound designed to avoid multidrug resistance mechanisms that limit the effectiveness of conventional anthracyclines in relapsed AML. Its combination with HiDAC (High-Dose Cytarabine) aims to enhance overall treatment efficacy beyond what HiDAC achieves alone.
Q: What does a composite complete remission rate of 57% mean clinically?
A: A composite complete remission (CRc) rate of 57% includes patients achieving complete remission (CR) as well as complete remission with incomplete blood count recovery (CRi), capturing the full spectrum of meaningful treatment responses. In relapsed AML where historical control arm rates are typically around 12%, a 57% composite rate represents a clinically significant improvement that would support continued development.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.